These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8336583)

  • 1. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial.
    MacLennan AH; MacLennan A; Wenzel S; Chambers HM; Eckert K
    Med J Aust; 1993 Jul; 159(2):102-6. PubMed ID: 8336583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oestrogen and cyclical progestogen in postmenopausal hormone replacement therapy.
    MacLennan AH; MacLennan A; O'Neill S; Kirkgard Y; Wenzel S; Chambers HM
    Med J Aust; 1992 Aug; 157(3):167-70. PubMed ID: 1321944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response.
    Raudaskoski T; Tapanainen J; Tomás E; Luotola H; Pekonen F; Ronni-Sivula H; Timonen H; Riphagen F; Laatikainen T
    BJOG; 2002 Feb; 109(2):136-44. PubMed ID: 11888095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.
    Lethaby A; Suckling J; Barlow D; Farquhar CM; Jepson RG; Roberts H
    Cochrane Database Syst Rev; 2004; (3):CD000402. PubMed ID: 15266429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate.
    Lundström E; Virijevic I; Söderqvist G
    Horm Mol Biol Clin Investig; 2020 Jul; 41(3):. PubMed ID: 32735552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
    Lethaby A; Hussain M; Rishworth JR; Rees MC
    Cochrane Database Syst Rev; 2015 Apr; (4):CD002126. PubMed ID: 25924648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding.
    Lethaby A; Farquhar C; Sarkis A; Roberts H; Jepson R; Barlow D
    Cochrane Database Syst Rev; 2000; (2):CD000402. PubMed ID: 10796715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone.
    von Holst T; Lang E; Winkler U; Keil D
    Maturitas; 2002 Dec; 43(4):265-75. PubMed ID: 12468135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
    Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmenopausal uterine bleeding profiles with two forms of continuous combined hormone replacement therapy.
    Johnson JV; Davidson M; Archer D; Bachmann G
    Menopause; 2002; 9(1):16-22. PubMed ID: 11791082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five years with continuous combined oestrogen/progestogen therapy. Effects on calcium metabolism, lipoproteins, and bleeding pattern.
    Christiansen C; Riis BJ
    Br J Obstet Gynaecol; 1990 Dec; 97(12):1087-92. PubMed ID: 2126198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy.
    Cano A; Tarín JJ; Dueñas JL
    Fertil Steril; 1999 Jan; 71(1):129-36. PubMed ID: 9935129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous combined conjugated equine estrogen-progestogen therapy: effects of medroxyprogesterone acetate and norethindrone acetate on bleeding patterns and endometrial histologic diagnosis.
    Hillard TC; Siddle NC; Whitehead MI; Fraser DI; Pryse-Davies J
    Am J Obstet Gynecol; 1992 Jul; 167(1):1-7. PubMed ID: 1442905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study.
    Wells M; Sturdee DW; Barlow DH; Ulrich LG; O'Brien K; Campbell MJ; Vessey MP; Bragg AJ
    BMJ; 2002 Aug; 325(7358):239. PubMed ID: 12153918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women.
    Cameron ST; Critchley HO; Glasier AF; Williams AR; Baird DT
    Br J Obstet Gynaecol; 1997 Oct; 104(10):1184-90. PubMed ID: 9332998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapy.
    Kwok S; Selby PL; McElduff P; Laing I; Mackness B; Mackness MI; Prais H; Morgan J; Yates AP; Durrington PN; Sci FM
    Clin Endocrinol (Oxf); 2004 Dec; 61(6):760-7. PubMed ID: 15579192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are fixed-dose oestrogen/progestogen combinations ideal for all HRT users?
    Fraser D; Whitehead MI; Endacott J; Morton J; Ryder TA; Pryse-Davies J
    Br J Obstet Gynaecol; 1989 Jul; 96(7):776-82. PubMed ID: 2765426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.